Inventor · disambiguated record
Hans G. Klingemann
Also filed as: KLINGEMANN HANS · KLINGEMANN HANS-G
45 granted patents·35 pending applications·284 citations·filing 2001–2025
98Inventor score
Top patents by PatentIndex Score
80 records- 0197US11230699B2Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptorsNANTKWEST INC·Filed 2020·Granted Jan 25, 2022·9 cites·27 claims
- 0297US11207350B2Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancerNANTKWEST INC·Filed 2021·Granted Dec 28, 2021·11 cites·11 claims
- 0397US11000550B2Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancerNANTKWEST INC·Filed 2020·Granted May 11, 2021·6 cites·9 claims
- 0496US11077143B2Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-expressing NK cellsNANTKWEST INC·Filed 2019·Granted Aug 3, 2021·16 cites·9 claims
- 0595US12384852B2Genetically modified NK-92 cells having a safety switchIMMUNITYBIO INC·Filed 2021·Granted Aug 12, 2025·2 cites·20 claims
- 0695US12109238B2Chimeric antigen receptor-modified NK-92 cellsIMMUNITYBIO INC·Filed 2022·Granted Oct 8, 2024·2 cites·17 claims
- 0795US11547727B2Chimeric antigen receptor-modified NK-92 cellsIMMUNITYBIO INC·Filed 2019·Granted Jan 10, 2023·10 cites·13 claims
- 0895US10960024B2Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapiesNANTKWEST INC·Filed 2019·Granted Mar 30, 2021·17 cites·18 claims
- 0995US10765701B2Elimination of CD19-positive lymphoid malignancies by CD19-CAR expressing NK cellsNANTKWEST INC·Filed 2019·Granted Sep 8, 2020·7 cites·25 claims
- 1095US10456420B2Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancerNANTKWEST INC·Filed 2016·Granted Oct 29, 2019·19 cites·11 claims
- 1194US12492377B2Modified NK-92 haNK003 cells for the clinicIMMUNITYBIO INC·Filed 2023·Granted Dec 9, 2025·1 cites·19 claims
- 1294US11643452B2Fc-epsilon carIMMUNITYBIO INC·Filed 2021·Granted May 9, 2023·6 cites·8 claims
- 1393US12403178B2Use of CD33CAR modified high affinity NK cells (t-haNK) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on NK cell activity)IMMUNITYBIO INC·Filed 2023·Granted Sep 2, 2025·2 cites·22 claims
- 1493US11207392B2Coordinated multi-prong cancer therapyNANT HOLDINGS IP LLC·Filed 2017·Granted Dec 28, 2021·5 cites·15 claims
- 1593US11129850B2Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapiesNANTKWEST INC·Filed 2019·Granted Sep 28, 2021·8 cites·4 claims
- 1693US11058723B2Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapiesNANTKWEST INC·Filed 2019·Granted Jul 13, 2021·8 cites·7 claims
- 1793US10736921B2Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancerNANTKWEST INC·Filed 2019·Granted Aug 11, 2020·5 cites·12 claims
- 1893US8034332B2Interleukin-secreting natural killer cell lines and methods of useCONKWEST INC·Filed 2003·Granted Oct 11, 2011·81 cites·1 claims
- 1992US10774310B2Modified NK-92 haNK003 cells for the clinicNANTKWEST INC·Filed 2019·Granted Sep 15, 2020·4 cites·11 claims
- 2092US2024366674A1Tumoricidal and antimicrobial compositions and methodsIMMUNITYBIO INC·Filed 2024·Application pending·0 cites
- 2191US11071774B2Nant cancer vaccineNANT HOLDINGS IP LLC·Filed 2020·Granted Jul 27, 2021·2 cites·16 claims
- 2291US10517895B2Tumoricidal and antimicrobial compositions and methodsNANTKWEST INC·Filed 2019·Granted Dec 31, 2019·5 cites·20 claims
- 2391US10258649B2Tumoricidal and antimicrobial compositions and methodsNANTKWEST INC·Filed 2014·Granted Apr 16, 2019·9 cites·17 claims
- 2490US12365874B2Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptorsIMMUNITYBIO INC·Filed 2021·Granted Jul 22, 2025·1 cites·18 claims
- 2589US12473348B2Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-expressing NK cellsIMMUNITYBIO INC·Filed 2021·Granted Nov 18, 2025·1 cites·18 claims
- 2689US12473347B2Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-expressing NK cellsIMMUNITYBIO INC·Filed 2021·Granted Nov 18, 2025·1 cites·18 claims
- 2789US10138462B2Natural killer cell lines and methods of useKLINGEMANN HANS·Filed 2001·Granted Nov 27, 2018·24 cites·1 claims
- 2888US10801013B2Modified NK-92 haNK003 cells for the clinicNANTKWEST INC·Filed 2018·Granted Oct 13, 2020·2 cites·14 claims
- 2988US2025340664A1Genetically modified nk-92 cell lineIMMUNITYBIO INC·Filed 2025·Application pending·0 cites
- 3087US12435122B2Fc-epsilon CARIMMUNITYBIO INC·Filed 2019·Granted Oct 7, 2025·3 cites·8 claims
- 3187US11813292B2Use of CD33CAR modified high affinity NK cells (t-haNK) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on NK cell activity)IMMUNITYBIO INC·Filed 2019·Granted Nov 14, 2023·2 cites·3 claims
- 3287US8124069B2Immunogenic peptidesBAE JOO-EUN·Filed 2009·Granted Feb 28, 2012·7 cites·10 claims
- 3386US12378300B2Elimination of CD19-positive lymphoid malignancies by CD19-car expressing NK cellsIMMUNITYBIO INC·Filed 2020·Granted Aug 5, 2025·1 cites·19 claims
- 3486US11753625B2Modified NK-92 haNK003 cells for the clinicNANTKWEST INC·Filed 2020·Granted Sep 12, 2023·1 cites·18 claims
- 3583US12180283B2Anti-B7-H4 chimeric antigen receptor-modified NK-92 cellsIMMUNITYBIO INC·Filed 2019·Granted Dec 31, 2024·1 cites·21 claims
- 3683US12064450B2Tumoricidal and antimicrobial compositions and methodsIMMUNITYBIO INC·Filed 2022·Granted Aug 20, 2024·0 cites·11 claims
- 3782US11975027B2Tumoricidal and antimicrobial compositions and methodsIMMUNITYBIO INC·Filed 2021·Granted May 7, 2024·0 cites·8 claims
- 3880US11364265B1Recombinant erIL-15 NK cellsNantCell·Filed 2020·Granted Jun 21, 2022·1 cites·20 claims
- 3980US2025073305A1Use of cd33car modified high affinity nk cells (t-hank) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on nk cell activity)IMMUNITYBIO INC·Filed 2024·Application pending·0 cites
- 4078US2025170181A1Tumoricidal and antimicrobial compositions and methodsIMMUNITYBIO INC·Filed 2025·Application pending·0 cites
- 4177US10646516B2Tumoricidal and antimicrobial compositions and methodsNANTKWEST INC·Filed 2018·Granted May 12, 2020·0 cites·18 claims
- 4277US2025066484A1Anti-B7-H4 Chimeric Antigen Receptor-Modified NK-92 CellsIMMUNITYBIO INC·Filed 2024·Application pending·0 cites
- 4376US2024366972A1Chimeric Antigen Receptor-Modified NK-92 CellsIMMUNITYBIO INC·Filed 2024·Application pending·0 cites
- 4476US2024252540A1Cell-mediated transient delivery of immune-enhancing molecules into the tumor microenvironmentIMMUNITYBIO INC·Filed 2024·Application pending·0 cites
- 4575US11439697B2Nant cancer vaccineNANTCELL INC·Filed 2021·Granted Sep 13, 2022·0 cites·20 claims
- 4675US2025270282A1Elimination of cd19-positive lymphoid malignancies by cd19-car expressing nk cellsIMMUNITYBIO INC·Filed 2025·Application pending·0 cites
- 4774US11304977B2Tumoricidal and antimicrobial compositions and methodsNANTKWEST INC·Filed 2019·Granted Apr 19, 2022·0 cites·5 claims
- 4874US7527793B2Immunogenic peptidesUNIV RUSH MEDICAL CENTER·Filed 2003·Granted May 5, 2009·4 cites·3 claims
- 4974US2023272042A1Fc-epsilon carIMMUNITYBIO INC·Filed 2023·Application pending·0 cites
- 5070US11213547B2Tumoricidal and antimicrobial compositions and methodsNANTKWEST INC·Filed 2019·Granted Jan 4, 2022·0 cites·17 claims
Showing the top 50 of 80 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Hans G. Klingemann files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →